SomnusNooze e-newsletter
News, stories and updates from the world of sleep
HF Welcomes Several New Board Members
The Board of Directors of the Hypersomnia Foundation is pleased to introduce three new board members to the Board of Directors, Scientific Advisory Board, and Medical Advisory Board. Diane Powell and to announce the appointment of two new members of the... read >
EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy
On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In... read >
Crash Course: Public School Accommodations for Children with Hypersomnia – Part 4
This is the last in a series of four articles explaining how to navigate the public school system for accommodations under a 504 plan. You can read the other parts here: part 1, part 2, and part 3. By Kate Pece, MEd A K-12 Idiopathic Hypersomnia Fact... read >
The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway
ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults. More than 20 study sites throughout the United States are... read >
Public School Accommodations for Children with Hypersomnia: Part 3
Crash Course: Public School Accommodations for Children with Hypersomnia By Kate Pece, MEd In this series of four articles, you will learn how to navigate the public school system for accommodations under a 504 plan. You can read the other parts... read >
BUNIHPPS – An Online Research Survey for Narcolepsy & IH Patients
https://www.hypersomniafoundation.org/research-study/bunihpps/ Dear IH Community members: A research team at Boston University has developed BUNIHPPS -- a survey research study for patients with narcolepsy and idiopathic hypersomnia. Also called the... read >
A Comparison of Sodium Oxybate in the Treatment of Idiopathic Hypersomnia and Narcolepsy Type 1
Background Sodium oxybate (SXB) is a drug sold as Xyrem in the United States by Jazz Pharmaceuticals, in Europe by UCB Pharma, and in Canada by Valeant Pharmaceuticals. It is approved in the United States in adults for the treatment of excessive daytime... read >
Research Opportunity
Victoria University, Melbourne Australia is commencing a study about the general health and well-being of people within three groups. One group will be those with both narcolepsy and cataplexy. Cataplexy is a sudden loss of muscle tone, often triggered... read >
The HF Welcomes Celia King to the Board of Directors
As we mentioned in our September 22, 2015, issue of SomnusNooze, several people have recently joined the Board of Directors of the Hypersomnia Foundation. Last month, we introduced you to Scot Hulshizer. Today, we would like you to meet Celia King. Ms.... read >
ADHD Symptoms in Children with Narcolepsy
Background Compared with adults with narcolepsy, children with narcolepsy often have higher levels of excessive daytime sleepiness (EDS), are more likely to have cataplexy without a trigger, and are more likely to have a secondary form of narcolepsy. The... read >